Background: Vulvovaginal candidiasis (VVC) usually is caused by Candida albicans but can occasionally be caused by other Candida sp. or yeasts. VVC can be classified as either uncomplicated or complicated. More than 90% of infections are uncomplicated VVC. CDC guidelines treatment of uncomplicated VVC oral Fluconazole 150 mg in a single dose or nystatin vaginal suppository 1 tab for 14 days. Treatment of complicated VVC oral fluconazole 150mg every third day for a total of 3 doses or topical azole antifungal therapy for 7-14 days.
Objectives: This study explores the rationality of using oral fluconazole, isoconazole vaginal suppository, and nystatin vaginal suppository.
Methods: This study is a retrospective study in a regional hospital. Cases were collected from January 2019 to December 2019 for all out-patients using oral fluconazole, isoconazole vaginal suppository, and nystatin vaginal suppository. To evaluate the utilization of drug for whether it meets CDC therapy guidelines.
Results: A total of 792 cases were diagnosed as VVC. 33 cases (4.2%) took oral fluconazole 150 mg, and among them, 21 cases (63.6%) used more than 1 single dose. 70 cases (8.8%) used isoconazole vaginal suppository, and among them, 1 case (1.4%) used more than 7 days. 689 cases (87%) took nystatin vaginal suppository, and 2 (0.3%) out of 689 cases used more than 14 days.
Conclusions: It is unreasonable taking oral fluconazole 150 mg more than 1 does. The results will also provide physicians with a review. The pharmacist intervened from January 2020 to May 2020. A total of 20 cases were diagnosed as VVC and 100% reasonable use. This study demonstrated the pharmacist intervention and collaboration with the physician reduced medical expenses.
